Sanofi SA ((SNY)), Sanofi ((DE:SNW)), Sanofi ((SNYNF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sanofi is conducting a study titled ‘A Phase 1/Phase 2, Randomized, Open-label, Multi Cohort, Multi Center, Study Assessing the Safety, Tolerability and Preliminary Efficacy of SAR443579 a Natural Killer Cell Engager (NKCE) Targeting CD123, Administered With Different Agents in Participants With CD123 Expressing Hematological Malignancies.’ The study aims to evaluate the safety, tolerability, and preliminary efficacy of SAR443579 in combination with other agents for treating hematological malignancies expressing CD123.
The intervention being tested is SAR443579, a natural killer cell engager, administered alongside azacitidine and venetoclax. These are intended to treat acute myeloid leukemia in patients ineligible for intensive chemotherapy.
The study is designed as an interventional, open-label, single-group assignment with no masking, focusing on treatment. It involves a safety run-in, dose optimization, and dose expansion phases to determine the optimal dosing strategy.
The study began on August 13, 2024, with a primary completion date yet to be announced. The latest update was submitted on July 25, 2025, indicating ongoing progress.
This study could significantly impact Sanofi’s stock performance by potentially introducing a novel treatment for hematological malignancies. Positive outcomes may enhance investor confidence and position Sanofi favorably against competitors in the oncology market.
The study is ongoing, with further details available on the ClinicalTrials portal.